Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571314 | 0.89 | AOC3 (0.45) | AOC3PDE1APDE1BPDE1CALOX5 | |
| SCHEMBL22435151 | 0.86 | AOC3 (0.43) | AOC3PDE1APDE1BPDE1CALOX5 | |
| SCHEMBL22571301 | 0.82 | AOC3 (0.49) | AOC3PDE1APDE1BPDE1CALOX5 | |
| SCHEMBL27587124 | 0.79 | AOC3 (0.43) | AOC3ALOX5CYP1A2 | |
| SCHEMBL27665354 | 0.79 | AOC3 (0.44) | AOC3 | |
| SCHEMBL27665224 | 0.78 | AOC3 (0.43) | AOC3 | |
| SCHEMBL9370526 | 0.77 | AOC3 (0.47) | AOC3ALOX5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5403166 | 0.77 | AOC3 (0.47) | AOC3ALOX5PTGS2SMN1; SMN2NPC1 | |
| SCHEMBL27665225 | 0.77 | AOC3 (0.42) | AOC3POLB | |
| SCHEMBL4987704 | 0.77 | AOC3 (0.42) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-10-22 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | AOC3 4610/4885PDE1A 817/4885PDE1B 1538/4885 |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | MAPK1, MAPK8, MAPK4 | AOC3 4630/4885PDE1A 1083/4885PDE1B 1649/4885 |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | AOC3 4630/4885PDE1A 1083/4885PDE1B 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.